103
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population

, , , , , , & show all
Pages 1-7 | Published online: 18 Dec 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Priyanka Gaitonde, Viktor Chirikov, Sneha Kelkar & Bengt Liljas. (2022) Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors. Cancer Management and Research 14, pages 3421-3435.
Read now
M. Sakil Syeed, Nabin Poudel, Surachat Ngorsuraches, Jose Diaz & Nathorn Chaiyakunapruk. (2022) Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review. Journal of Medical Economics 25:1, pages 1176-1184.
Read now
O. Leeuwenkamp, J. Smith-Palmer, R. Ortiz, A. Werner, W. Valentine, M. Blachier & T. Walter. (2020) Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. Journal of Medical Economics 23:12, pages 1534-1541.
Read now
Elizabeth Mostofsky, Jillian A Dunn, Sonia Hernández-Díaz, Anna C Johansson & Murray A Mittleman. (2019) Eliciting stakeholder preferences for patient-centered research. Patient Preference and Adherence 13, pages 339-349.
Read now
Oriol Solà-Morales, Timm Volmer & Lorenzo Mantovani. (2019) Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. Journal of Market Access & Health Policy 7:1.
Read now
Pricivel Carrera & Maarten J. IJzerman. (2016) Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare. Expert Review of Pharmacoeconomics & Outcomes Research 16:4, pages 435-437.
Read now

Articles from other publishers (3)

Elizabeth Beaulieu, Anne Spanjaart, Ashley Roes, Bernard Rachet, Stéphane Dalle, Marie José Kersten, Delphine Maucort-Boulch & Mohammad S. Jalali. (2022) Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. Quality of Life Research 31:8, pages 2357-2366.
Crossref
Khalid El Bairi, Ouissam Al Jarroudi, Laura Carpenito, Dario Trapani & Said Afqir. 2021. Ovarian Cancer Biomarkers. Ovarian Cancer Biomarkers 167 185 .
Natalie Ertz-Archambault & Nandita Khera. (2020) Navigating Ethical Practices in the Era of High Cost Hematology. Current Hematologic Malignancy Reports 15:5, pages 401-407.
Crossref